Search bioRxivSearch

Biology subjects

Min Chen

Publications and source records attributed to Min Chen.

2 recordsLinked to original sources

RSQ: a statistical method for quantification of isoform-specific structurome using transcriptome-wide structural profiling data

The structure of RNA, which is considered to be a second layer of information alongside the genetic code, provides fundamental insights into the cellular function of both coding and non-coding RNAs. Several high-throughput technologies have been developed to profile transcriptome-wide RNA structures, i.e., the structurome. However, it is challenging to interpret the profiling data because the observed data represent an average over different RNA conformations and isoforms with different abundance. To address this challenge, we developed an RNA structurome quantification method (RSQ) to statistically model the distribution of reads over both isoforms and RNA conformations, and thus provide accurate quantification of the isoform-specific structurome. The quantified RNA structurome enables the comparison of isoform-specific conformations between different conditions, the exploration of RNA conformation variation affected by single nucleotide polymorphism (SNP),and the measurement of RNA accessibility for binding of either small RNAs in RNAi-based assays or RNA binding protein in transcriptional regulation. The model used in our method sheds new light on the potential impact of the RNA structurome on gene regulation.

Bioinformatics

An integrative somatic mutation analysis to identify pathways linked with survival outcomes across 19 cancer types

Identification of altered pathways that are clinically relevant across human cancers is a key challenge in cancer genomics. We developed a network-based algorithm to integrate somatic mutation data with gene networks and pathways, in order to identify pathways altered by somatic mutations across cancers. We applied our approach to The Cancer Genome Atlas (TCGA) dataset of somatic mutations in 4,790 cancer patients with 19 different types of malignancies. Our analysis identified cancer-type-specific altered pathways enriched with known cancer-relevant genes and drug targets. Consensus clustering using gene expression datasets that included 4,870 patients from TCGA and multiple independent cohorts confirmed that the altered pathways could be used to stratify patients into subgroups with significantly different clinical outcomes. Of particular significance, certain patient subpopulations with poor prognosis were identified because they had specific altered pathways for which there are available targeted therapies. These findings could be used to tailor and intensify therapy in these patients, for whom current therapy is suboptimal.

Bioinformatics